Bio-Rad Laboratories financials
$379.55+0.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $651.0M | $592.1M | $693.2M | $653.0M | $651.6M | $585.4M | $667.5M | $649.7M | $638.5M | $610.8M | $681.1M | $632.1M |
| Gross profit | $345.8M | $309.4M | $345.2M | $343.4M | $345.3M | $306.0M | $341.9M | $355.9M | $355.1M | $325.9M | $366.3M | $335.7M |
| Gross margin | 53.1% | 52.3% | 49.8% | 52.6% | 53.0% | 52.3% | 51.2% | 54.8% | 55.6% | 53.4% | 53.8% | 53.1% |
| Operating income | $72.6M | $34.1M | $53.9M | $65.3M | $77.1M | $23.7M | $58.3M | $64.5M | $101.5M | $44.6M | $95.3M | $90.9M |
| Net income | $371.4M | -$527.1M | $720.0M | -$341.9M | $317.8M | $64.0M | -$715.8M | $653.2M | -$2.17B | $383.9M | $349.7M | $106.3M |
| Net margin | 57.1% | −89.0% | 103.9% | −52.4% | 48.8% | 10.9% | −107.2% | 100.5% | −339.2% | 62.9% | 51.3% | 16.8% |
| Diluted EPS | $13.85 | $-19.55 | $26.65 | $-12.70 | $11.67 | $2.29 | $-25.62 | $23.34 | $-76.26 | $13.45 | $12.27 | $3.64 |
| EBITDA | $72.6M | $34.1M | $53.9M | $65.3M | $77.1M | $23.7M | $58.3M | $64.5M | $101.5M | $44.6M | $95.3M | $19.5M |
| Operating cash flow | $98.7M | $108.1M | $164.9M | $120.9M | $116.5M | $129.9M | $124.2M | $163.6M | $97.6M | $69.8M | $99.1M | $97.7M |
| Free cash flow | $66.7M | $78.1M | $119.1M | $89.2M | $70.8M | $95.5M | $81.3M | $123.4M | $55.3M | $29.6M | $56.8M | $53.6M |
| Diluted shares | 26.8M | 27.0M | 27.0M | 26.9M | 27.2M | 28.0M | 27.9M | 28.0M | 28.4M | 28.5M | 28.5M | 29.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $517.0M | $507.2M | $529.8M | $395.8M | $369.3M | $521.4M |
| Short-term investments | $1.10B | $1.06B | $1.01B | $1.02B | $1.00B | $1.14B |
| Total debt | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B |
| Total assets | $10.25B | $9.79B | $10.58B | $9.70B | $10.21B | $9.53B |
| Total liabilities | $3.08B | $2.94B | $3.12B | $2.96B | $3.09B | $2.85B |
| Shareholders' equity | $7.17B | $6.85B | $7.45B | $6.74B | $7.13B | $6.68B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology